Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer


Manage episode 245585462 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

172 episodes